MedTrace Logo

Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial

NCT06548204 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2024-08-12

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.

Conditions

  • ST-segment Elevation Myocardial Infarction (STEMI)

Interventions

DRUG

Fexofenadine Hydrochloride 60mg bid

Fexofenadine hydrochloride 60mg bid treatment for 6 months.

OTHER

Placebo

Placebo administration for 6 months.

DRUG

Fexofenadine Hydrochloride 120mg bid

Fexofenadine hydrochloride 120mg bid treatment for 6 months.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Xinyang Hu, PhD · 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2026-03-31
Completion
2026-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06548204 on ClinicalTrials.gov